NL300246I1 - Werkwijze voor het voorkomen van zoster en verlichting van met varicella verwante post-herpes neuralgie. - Google Patents

Werkwijze voor het voorkomen van zoster en verlichting van met varicella verwante post-herpes neuralgie.

Info

Publication number
NL300246I1
NL300246I1 NL300246C NL300246C NL300246I1 NL 300246 I1 NL300246 I1 NL 300246I1 NL 300246 C NL300246 C NL 300246C NL 300246 C NL300246 C NL 300246C NL 300246 I1 NL300246 I1 NL 300246I1
Authority
NL
Netherlands
Prior art keywords
varicella
alleviation
related post
zoster
herpes neuralgia
Prior art date
Application number
NL300246C
Other languages
English (en)
Other versions
NL300246I2 (nl
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25435290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300246(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NL300246I1 publication Critical patent/NL300246I1/nl
Publication of NL300246I2 publication Critical patent/NL300246I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NL300246C 1992-07-17 2006-11-08 Werkwijze voor het voorkomen van zoster en verlichting van met varicella. NL300246I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91514192A 1992-07-17 1992-07-17
PCT/US1993/006581 WO1994002596A1 (en) 1992-07-17 1993-07-13 Method for preventing zoster or alleviating varicella related post-herpetic neuralgia

Publications (2)

Publication Number Publication Date
NL300246I1 true NL300246I1 (nl) 2007-01-02
NL300246I2 NL300246I2 (nl) 2007-02-01

Family

ID=25435290

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300246C NL300246I2 (nl) 1992-07-17 2006-11-08 Werkwijze voor het voorkomen van zoster en verlichting van met varicella.

Country Status (15)

Country Link
US (2) US5997880A (nl)
EP (1) EP0651789B2 (nl)
JP (3) JP4562812B2 (nl)
AT (1) ATE210722T1 (nl)
AU (1) AU687355B2 (nl)
CA (1) CA2139515C (nl)
CY (1) CY2286B1 (nl)
DE (2) DE69331322T3 (nl)
DK (1) DK0651789T4 (nl)
ES (1) ES2165367T5 (nl)
LU (1) LU91287I2 (nl)
LV (1) LV12832B (nl)
NL (1) NL300246I2 (nl)
PT (1) PT651789E (nl)
WO (1) WO1994002596A1 (nl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
CN102046121A (zh) 2008-04-04 2011-05-04 3M创新有限公司 具有微型泵的伤口敷料
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
EP3041505A4 (en) 2013-09-05 2017-04-19 Merck Sharp & Dohme Corp. Methods of immunization with varicella zoster virus antigen
WO2017079582A1 (en) 2015-11-06 2017-05-11 Adjuvance Technologies, Inc. Triterpene saponin analogues

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US376788A (en) * 1888-01-24 strait
US441737A (en) * 1890-12-02 Tapping-machine for stay-bolt holes
JPS5341202B2 (nl) * 1974-03-12 1978-11-01
US4000256A (en) * 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
US4008317A (en) * 1975-12-29 1977-02-15 Recherche Et Industrie Therapeutiques (R.I.T.) Varicella-zoster virus vaccine and preparation thereof
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
DK332683A (da) * 1982-07-20 1984-01-21 Bio Com Inc Fremgangsmaade til fremstilling af en transfer-faktor for et givet virus
US4769239A (en) * 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
EP0211756A1 (en) * 1985-08-01 1987-02-25 Merck & Co. Inc. Assay for varicella-zoster virus (VZV) antibodies
US4686101A (en) * 1985-08-02 1987-08-11 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4952674A (en) * 1986-05-02 1990-08-28 Merck & Co., Inc. Vaccine against varicella-zoster virus
NZ220645A (en) * 1986-06-20 1989-10-27 Merck & Co Inc Modified varicella-zoster virus and its cultivation
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
DK0405867T3 (da) * 1989-06-27 1995-05-22 Smithkline Beecham Biolog Hidtil ukendte forbindelser
DE69132404T2 (de) * 1990-10-04 2001-02-15 Research Corp. Technologies, Inc. Varicella-zoster virusantigen

Also Published As

Publication number Publication date
JP4562812B2 (ja) 2010-10-13
CA2139515A1 (en) 1994-02-03
JP2004323531A (ja) 2004-11-18
LV12832B (en) 2002-09-20
ATE210722T1 (de) 2001-12-15
LV12832A (en) 2002-05-20
EP0651789A1 (en) 1995-05-10
EP0651789B2 (en) 2009-05-20
DK0651789T3 (da) 2002-03-11
US6214354B1 (en) 2001-04-10
DK0651789T4 (da) 2009-07-27
DE69331322T2 (de) 2002-08-08
WO1994002596A1 (en) 1994-02-03
DE69331322T3 (de) 2009-10-22
ES2165367T3 (es) 2002-03-16
ES2165367T5 (es) 2009-08-05
AU4676093A (en) 1994-02-14
US5997880A (en) 1999-12-07
EP0651789A4 (en) 1996-06-26
JPH07509244A (ja) 1995-10-12
EP0651789B1 (en) 2001-12-12
JP2010189420A (ja) 2010-09-02
LU91287I2 (fr) 2007-01-15
NL300246I2 (nl) 2007-02-01
CY2286B1 (en) 2003-07-04
AU687355B2 (en) 1998-02-26
DE122006000063I1 (de) 2007-05-10
DE69331322D1 (de) 2002-01-24
CA2139515C (en) 2008-12-23
PT651789E (pt) 2002-05-31

Similar Documents

Publication Publication Date Title
NL300246I1 (nl) Werkwijze voor het voorkomen van zoster en verlichting van met varicella verwante post-herpes neuralgie.
BR9907283A (pt) Vìrus do herpes simples, uso de um vìrus do herpes simples, composição farmacêutica, e, processos para estudar a função de gene heterólogo em uma célula de mamìfero e para produzir um vìrus do herpes simples
NO951212L (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
AU1866895A (en) Human monoclonal antibodies to herpes simplex virus and methods therefor
Ap Understanding host residents' perceptions of the impacts of tourism through social exchange theory
DK0630368T3 (da) Antivirale nukleosidanaloge
DE59204683D1 (de) Vorrichtung zur verdeckten aufhängung von platten an trägerkonstruktionen
ATE211148T1 (de) Hcmv-spezifische peptide und ihre verwendung
Garstang Improved scattering formula for calculations of artificial night-sky illumination
BORDERIE LIGHT FRAGMENT EMISSION AND MULTIFRAGMENTATION?
ATA99594A (de) Verfahren zur herstellung von 2-amino-4,6-dichloro-pyrimidin
WO2002088327A1 (en) Methods for viral oncoapoptosis in cancer therapy
MX9300744A (es) Particula ligera herpetica, formulacion de vacuna que la contiene y metodo para la produccion de dicha vacuna.
Banerjee Corrections and amendments
Goloviznin et al. Highly implicit finite-difference schemes for gasdynamics.
Triger et al. Viral antibodies and autoantibodies in chronic liver disease.
Todd et al. Standards of Seismic Safety for Existing Federally Owned Or Leased Buildings and Commentary
GR1001494B (el) Κλειδαριά συρομένων κουφωμάτων κατακορύφου πύρου ασφάλισης και μεταλλικού δακτυλιοειδούς αντικρύσματος.
Sundararajan Comment on Professor Johnson’s Article on Computer Language
Durum et al. T cell interleukin 1
HOORNAERT On the Conflicting Interpretations of “Sunyata” by the Madhyamika and the Yogacara
NAZARALIEV Statistical modeling of radiation processes in the atmosphere(Russian book)(Statisticheskoe modelirovanie radiatsionnykh protsessov v atmosfere)
FI884757A (fi) Anordning foer upplysning av trappuppgaonger i hoeghus.
Oh et al. Suppressive Effect of Cyclosporine on the Induction of Secondary Herpes Simplex Uveitis
OH SUPPRESSIVE EFFECT OF CYCLOSPORINE ON THE INDUCTION OF SECON-DARY HERPES SIMPLEX UVEITIS JANG O. OH, PETROS MINASI, GUNTHER GRABNER, YUICHI OHASI